CLASS II Drug recall · Reported 16 Oct 2019 · FDA Enforcement Report
Optiray 320 (ioversol) Injection recalled by Guerbet
Guerbet is recalling Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, distributed nationwide in the US. The recall was initiated on 13 Sep 2019 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0137-2020
- FDA event ID
- 83798
- Recalling firm
- Guerbet, Princeton, NJ
- Brand
- Optiray
- Manufacturer
- Liebel-Flarsheim Company LLC
- Classification
- Class II
- Status
- Terminated
- Recall initiated
- 13 Sep 2019
- FDA classified
- 9 Oct 2019
- Reported
- 16 Oct 2019
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Packaging Defects
- Drug class
- Injectable & IV Drugs
Timeline
| 13 Sep 2019 | Recall initiated by company | |
| 9 Oct 2019 | Classified by FDA | +26 days |
| 16 Oct 2019 | Published in enforcement report | +7 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.
Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.
Product as listed by the FDA
Optiray 320 (ioversol) Injection 68%, 320 mg/mL Organically Bound Iodine, packaged in 1 - 100 mL Ultraject Prefilled Syringe For Power Injection per carton, RFID Technology, Rx Only, Manufactured by: Liebel-Flarshelm Company, LLC., Raleigh, NC 27616; NDC 0019-1323-00.
Where it was distributed
Nationwide in the USA
Questions about this recall
Why was it recalled?
Labeling: Not Elsewhere Classified: RFID formatting error which reads product in Ultraject syringe as expired and will not allow injection of product by the Optivantage injector.
Which lots are affected?
Lots: L141C, L162A Exp. 06/2021; L146DS, Exp. 05/2021
Where was it sold?
Nationwide in the USA
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
Other products in this recall event
1 other product · FDA event 83798This product is part of a recall event; the main page for the event is Sodium Chloride Injection recalled by Guerbet.
| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| CLASS III | Sodium Chloride Injection recalled by GuerbetSodium Chloride | Guerbet | Packaging Defects | Nationwide |
More recalls from Guerbet
All 2| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS III | Sodium Chloride Injection recalled by GuerbetSodium Chloride | Guerbet | Packaging Defects | Nationwide |
Other Ioversol recalls
All 2| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS I | Optiray Imaging -350, Ioversol Injection recalledOptiray | Liebel-Flarsheim | Particulate Matter | Nationwide |